Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Benign Prostatic Hyperplasia Studio randomizzato, in doppio cieco, controllato con placebo per valutare lâeffetto di tadalafil somministrato una volta/die per 8 settimane sui parametri di flusso ematico prostatico e di perfusione negli uomini con segni e sintomi di ipertrofia prostatica benigna
Evaluate the effect of tadalafil 5 mg once daily for 8 weeks compared with placebo on improving prostatic blood perfusion in men with signs and symptoms of BPH, also referred to as BPH-LUTS (lower uri...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus
The primary objective of this study is to test the hypothesis that, for adult patients with T2DM treated with or without metformin, administration of LY2599506 significantly decreases the HbA1c from b...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea
to estimate difference in change in HbA1c from baseline to treatment endpoint (26 weeks) between 2.0 mg exenatide LAR once weekly and insulin glargine QD in patients with type 2 diabetes and inadequa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)
To assess whether ixekizumab is superior to placebo at Week 12 in the treatment of patients with moderate-to-severe genital psoriasis
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
To compare the effect of tadalafil 20 mg once a day for 12 weeks on detrusor pressure at peak urinary flow rate versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study in patients with Myelodysplastic Syndromes
Phase 2 portion To estimate the distribution of best HI, based on IWG 2006 criteria in patients with very low-, low-, and intermediate-risk MDS by IPSS-R treated with LY2157299 plus best supportive c...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Phase 2 Study in Patients With Moderate-to-Severe Psoriasis
The primary objective of this study is to test the hypothesis that at least 1 LY2439821 treatment group is superior to placebo in the proportion of adult patients with moderate-to-severe chronic plaqu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
The primary objective of Study H3E-MC-JMHW (JMHW) was to estimate the response rates to pemetrexed administered intravenously every 21 days in children with relapsed or refractory osteosarcoma, Ewin...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes
To test the hypothesis that exenatide once weekly is superior to metformin, sitagliptin, and pioglitazone in HbA1c reduction at 26 weeks compared to baseline, in drug-naive patients with type 2 diabet...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Randomized Trial Comparing Exenatide with Placebo in Subjects with Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications
to test the hypothesis that twice daily exenatide plus titration of basal insulin is superior to placebo plus titration of basal insulin on glycemic control as measured by change in A1C from baseline ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next